Mavorixafor for treating WHIM syndrome ID3946
Awaiting development [GID-TA10833] Expected publication date: TBC
Search results
231 results
-
-
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Awaiting development [GID-TA10752] Expected publication date: TBC
-
Intravenous zanamivir for treating influenza in hospital [ID1196]
Awaiting development [GID-TA10298] Expected publication date: TBC
-
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]
Awaiting development [GID-TA10758] Expected publication date: TBC
-
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Awaiting development [GID-TA10700] Expected publication date: TBC
-
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Awaiting development [GID-TA10774] Expected publication date: TBC
-
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Awaiting development [GID-TA10776] Expected publication date: TBC
-
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Awaiting development [GID-TA10604] Expected publication date: TBC
-
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Awaiting development [GID-TA10638] Expected publication date: TBC
-
Remimazolam for general anaesthesia [ID3796]
Awaiting development [GID-TA10679] Expected publication date: TBC
-
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Awaiting development [GID-TA10682] Expected publication date: TBC
-
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]
Awaiting development [GID-TA10684] Expected publication date: TBC
-
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]
Awaiting development [GID-TA10685] Expected publication date: TBC
-
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Awaiting development [GID-TA10553] Expected publication date: TBC
-
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]
Awaiting development [GID-TA10783] Expected publication date: TBC
-
Timrepigene emparvovec for treating choroideremia [ID3916]
Awaiting development [GID-TA10787] Expected publication date: TBC
-
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]
Awaiting development [GID-TA10791] Expected publication date: TBC
-
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]
Awaiting development [GID-TA10797] Expected publication date: TBC
-
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]
Awaiting development [GID-TA10800] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]
Awaiting development [GID-TA10811] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]
Awaiting development [GID-TA10813] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3933]
Awaiting development [GID-TA10815] Expected publication date: TBC
-
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Awaiting development [GID-TA10823] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Awaiting development [GID-TA10826] Expected publication date: TBC
-
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]
Awaiting development [GID-TA10722] Expected publication date: TBC
-
Benralizumab for previously treated severe nasal polyps [ID1659]
Awaiting development [GID-TA10818] Expected publication date: TBC
-
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Awaiting development [GID-TA10662] Expected publication date: TBC
-
Sotagliflozin for treating type 2 diabetes [ID1657]
Awaiting development [GID-TA10665] Expected publication date: TBC
-
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Awaiting development [GID-TA10694] Expected publication date: TBC
-
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]
Awaiting development [GID-TA10574] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]
Awaiting development [GID-TA10707] Expected publication date: TBC
-
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]
Awaiting development [GID-TA10715] Expected publication date: TBC
-
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Awaiting development [GID-TA10717] Expected publication date: TBC
-
Cannabidiol for treating seizures caused by tuberous sclerosis complex [ID1416]
Awaiting development [GID-TA10840] Expected publication date: 23 November 2022
-
Etranacogene dezaparvovec for treating haemophilia B [ID3812]
Awaiting development [GID-TA10699] Expected publication date: TBC
-
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Awaiting development [GID-TA10904] Expected publication date: TBC
-
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma after a BTK inhibitor [ID3975]
Awaiting development [GID-TA10858] Expected publication date: 16 August 2023
-
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Awaiting development [GID-TA10745] Expected publication date: 07 February 2024
-
Daridorexant for treating insomnia disorder [ID3774]
Awaiting development [GID-TA10888] Expected publication date: 16 August 2023
-
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]
Awaiting development [GID-TA10788] Expected publication date: TBC
-
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (ID3961)
Awaiting development [GID-TA10938] Expected publication date: TBC
-
Regorafenib for previously treated metastatic colorectal cancer [ID4002]
Awaiting development [GID-TA10924] Expected publication date: 01 February 2023
-
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer TS ID 10759
Awaiting development [GID-TA11021] Expected publication date: TBC
-
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma TS ID 10757
Awaiting development [GID-TA11019] Expected publication date: TBC
-
OrganOx metra for preserving livers for transplant [ID5516]
Awaiting development [GID-TA11035] Expected publication date: TBC
-
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 6 June 2022.
-
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]
Awaiting development [GID-TA11033] Expected publication date: TBC
-
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
Awaiting development [GID-TA10900] Expected publication date: TBC
-
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
Awaiting development [GID-TA10899] Expected publication date: TBC
-
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 13 June 2022.